Larissa Savelyeva Selected Research

Neoplasms (Cancer)

8/2013	Instability at the FRA8I common fragile site disrupts the genomic integrity of the KIAA0146, CEBPD and PRKDC genes in colorectal cancer.
5/2013	Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.
12/2012	HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
4/2011	The FRA2C common fragile site maps to the borders of MYCN amplicons in neuroblastoma and is associated with gross chromosomal rearrangements in different cancers.
2/2007	FRA1E common fragile site breaks map within a 370kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Larissa Savelyeva Research Topics

Disease

6	Neuroblastoma 01/2021 - 11/2003
5	Neoplasms (Cancer) 08/2013 - 02/2007
4	Carcinogenesis 08/2013 - 07/2003
2	Neoplasm Metastasis (Metastasis) 01/2020 - 08/2008
2	Genomic Instability 11/2006 - 01/2003
1	Disease Progression 10/2015
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/2013
1	Chromosome Aberrations (Chromosome Abnormalities) 04/2013
1	Medulloblastoma 12/2012
1	Isochromosomes 12/2012
1	Retinoblastoma (Glioblastoma, Retinal) 06/2008
1	Polyploidy 11/2007
1	Inborn Genetic Diseases (Disease, Hereditary) 11/2007
1	Chromosomal Instability (Chromosome Stability) 07/2004
1	Colorectal Neoplasms (Colorectal Cancer) 07/2003

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 08/2013 - 07/2003
3	DNA (Deoxyribonucleic Acid)IBA 04/2011 - 01/2003
3	BRCA2 ProteinIBA 11/2007 - 07/2004
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021 - 10/2015
2	Tumor Suppressor Protein p14ARF (p14ARF)IBA 05/2013 - 04/2013
2	Histone Deacetylase InhibitorsIBA 12/2012 - 06/2008
1	ProteomeIBA 01/2021
1	NucleotidesIBA 01/2020
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 08/2013
1	Ligases (Synthetase)IBA 05/2013
1	ChromatinIBA 05/2013
1	UbiquitinIBA 05/2013
1	Cyclin-Dependent Kinase Inhibitor p16IBA 05/2013
1	Trans-Activators (Trans-Acting Factor)IBA 05/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2013
1	Glial Fibrillary Acidic ProteinIBA 12/2012
1	Biomarkers (Surrogate Marker)IBA 08/2008
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 06/2008
1	HC toxinIBA 06/2008
1	AphidicolinIBA 11/2007
1	ThymineIBA 02/2007
1	Fluorouracil (Carac)FDA LinkGeneric 02/2007
1	N-Myc Proto-Oncogene ProteinIBA 11/2003
1	ThioredoxinsIBA 11/2003
1	CytokinesIBA 11/2003
1	Protein Disulfide-IsomerasesIBA 11/2003
1	Interferon-gamma (Interferon, gamma)IBA 11/2003
1	Protein Sorting Signals (Signal Peptide)IBA 11/2003
1	sulfhydryl oxidaseIBA 11/2003
1	Amino Acids FDA Link 11/2003
1	Cytostatic AgentsIBA 11/2003
1	aflatoxin B1 aldehyde reductaseIBA 07/2003
1	AflatoxinsIBA 07/2003

Therapy/Procedure

1	Combined Modality Therapy 10/2015
1	Transplantation 12/2012
1	Therapeutics 08/2008